NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.